Anteris Technologies Global Corp.

Anteris is a structural heart company dedicated to revolutionizing cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Our lead product, the DurAVR THV System, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from a narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Our DurAVR THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT tissue-enhancing technology and deployed with our balloon expandable ComASUR Delivery System. ADAPT is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Our patented ADAPT tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, according to Performance of the ADAPT-Treated CardioCel Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes , published by William Neethling et. al., and has been distributed for use in over 55,000 patients globally in other indications.